secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001711279-25-000013
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech receives positive CHMP opinion for VYJUVEK in EU; EC decision expected Q2 2025
--------------------------------------------------------------------------------

- CHMP recommends EC approval of VYJUVEK for DEB wounds, including from birth, with option for at-home administration.
- Final EC decision anticipated in Q2 2025, applicable to EU member states plus Iceland, Norway, Liechtenstein.
- Positive opinion based on Phase 1/2 GEM-1 and Phase 3 GEM-3 data showing durable wound closure.
- Company expects first European launch in Germany around mid-2025, followed by France later in 2025.
- VYJUVEK previously approved by FDA in May 2023 for DEB patients aged 6 months and older in the U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000013/0001711279-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000013/krys-20250228.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer